VTV THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.04 USD | -2.83% |
|
-1.99% | +109.04% |
| Mar. 14 | VTv Therapeutics Inc. Announces Board Changes | CI |
| Mar. 13 | VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2022 | 2.02M | Sales 2023 | - | Capitalization | 23.43M |
|---|---|---|---|---|---|
| Net income 2022 | -19M | Net income 2023 | -20M | EV / Sales 2022 | 21.1 x |
| Net cash position 2022 | 11.42M | Net cash position 2023 | 8.98M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.59
x | P/E ratio 2023 |
-1.18
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 41.41% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.83% | ||
| 1 week | -1.99% | ||
| Current month | +2.17% | ||
| 1 month | +15.02% | ||
| 3 months | +186.53% | ||
| 6 months | +39.77% | ||
| Current year | +109.04% |
1 week
23.00
25.00
1 month
19.1230.99
Current year
7.3830.99
1 year
7.3839.60
3 years
7.38115.20
5 years
7.38190.00
10 years
7.38560.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Sekhri
CEO | Chief Executive Officer | 66 | 22-07-31 |
Steven Tuch
DFI | Director of Finance/CFO | 56 | 22-12-07 |
Vanessa McDade
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Srini Akkaraju
BRD | Director/Board Member | 56 | Feb. 26 |
Paul Sekhri
CEO | Chief Executive Officer | 66 | 22-07-31 |
Richard Nelson
BRD | Director/Board Member | 54 | 20-11-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 24.04 | -2.83% | 1,989 |
| 24-04-18 | 24.74 | +2.44% | 3,423 |
| 24-04-17 | 24.15 | +0.08% | 16,497 |
| 24-04-16 | 24.13 | -3.48% | 5,229 |
| 24-04-15 | 25 | +1.93% | 11,659 |
Delayed Quote Nasdaq, April 19, 2024 at 04:30 pm EDT
More quotes
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +109.04% | 60.19M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- VTVT Stock
